Prometic receives clearance for phase 2 clinical trial

Omnio’s licensee Prometic Life Sciences (TSX:PLI) has announced that they have received approval from the Swedish Medical Products Agency (L√§kemedelsverket) to commence a Phase I/II clinical trial of the plasminogen therapy in patients suffering from Diabetic Foot Ulcer.

Read full release

Comments are closed.